high-risk atherosclerotic cardiovascular disease (ASCVD)
Conditions
Interventions
statin:N/A
Hybutimibe Tablets and statin:N/A
Sponsors
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Aged>=18 years, male or female. 2.Diagnosed with very high-risk atherosclerotic cardiovascular disease (ASCVD). 3.Treated with a fixed-dose combination regimen of Hybutimibe tablets added to background statin therapy. 4.Availability of at least two or more follow-up visit records.
Exclusion criteria
Exclusion criteria: 1.Presence of other diseases or factors that may lead to secondary hypercholesterolemia, such as nephrotic syndrome, hypothyroidism, etc., or patients with drug-induced hypercholesterolemia. 2.Cases with incomplete medical records that preclude accurate assessment of drug exposure, efficacy, or safety. 3.Concurrent use of other medications affecting efficacy evaluation and safety, such as PCSK9 inhibitors, Xuezhikang, etc. (except for patients on stable therapy prior to the initiation of Hybutimibe combination treatment). 4.Vulnerable populations, including individuals with mental illness, cognitive impairment, critically ill patients, minors, and female subjects who are pregnant, lactating, or with a positive pregnancy test. 5.Any other conditions deemed by the investigator as unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiac enzyme profile;Adverse Events (AEs) and Serious Adverse Events (SAEs);TC?TG?HDL-C?LDL-C?Apo B;Liver and kidney function; | — |
Secondary
| Measure | Time frame |
|---|---|
| Administration Details; | — |
Countries
China
Contacts
Public ContactWenbin Zhang
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Outcome results
None listed